Fractyl reports durable weight maintenance after GLP-1 discontinuation
Data show optimized patients maintained 84% of prior GLP-1-induced weight loss vs 46% for sham, with no serious device-related events; REVEAL-1 corroborates results.
See the latest news and media coverage for Fractyl. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of metabolic therapies for obesity and type 2 diabetes
fractyl.comLast updated
In short: Fractyl Health reported positive clinical data for its Revita procedure and initiated its first human gene therapy trial in 2026.
Data show optimized patients maintained 84% of prior GLP-1-induced weight loss vs 46% for sham, with no serious device-related events; REVEAL-1 corroborates results.
One-year REMAIN-1 data show durable weight maintenance after Revita, with pivotal readout expected early Q4 2026 and cash runway into early 2027.
Revita maintained 84% of weight loss vs 46% with sham at one year in optimized cohort.
Patients retained ~78% of GLP-1-induced weight loss after a single procedure; 33% continued losing weight.
July 15 Fractyl Health releases one-year results from the REMAIN-1 intermediate cohort demonstrating sustained weight maintenance after discontinuation of GLP-1 CI...
Fractyl Health (NASDAQ:GUTS) outlined a commercial strategy for its investigational Revita procedure, positioning the one-time endoscopic therapy as a potential option for patients seeking to...
Fractyl Health developed a minimally invasive system that has helped patients maintain up to 84% of GLP-1-induced weight loss.
September 3, 2026) - Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities...
Track Fractyl and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Fractyl and other trending companies.